Barclays PLC raised its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 24.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 569,892 shares of the company's stock after acquiring an additional 110,371 shares during the period. Barclays PLC owned approximately 0.08% of Roivant Sciences worth $6,742,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in ROIV. Virtu Financial LLC bought a new stake in Roivant Sciences during the third quarter worth $207,000. Te Ahumairangi Investment Management Ltd raised its holdings in shares of Roivant Sciences by 19.9% in the third quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company's stock valued at $2,313,000 after purchasing an additional 33,467 shares during the last quarter. Tyro Capital Management LLC lifted its position in shares of Roivant Sciences by 0.6% during the third quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company's stock valued at $20,252,000 after purchasing an additional 10,649 shares in the last quarter. Retirement Systems of Alabama boosted its holdings in Roivant Sciences by 26.9% during the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after purchasing an additional 112,286 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Roivant Sciences by 4.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 822,582 shares of the company's stock valued at $9,493,000 after buying an additional 34,453 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.
Roivant Sciences Price Performance
Shares of Roivant Sciences stock traded up $0.33 during trading hours on Wednesday, reaching $11.62. The company had a trading volume of 6,880,921 shares, compared to its average volume of 5,482,924. Roivant Sciences Ltd. has a one year low of $8.73 and a one year high of $13.06. The firm has a market cap of $8.29 billion, a PE ratio of -77.46 and a beta of 1.25. The business has a fifty day simple moving average of $10.36 and a 200 day simple moving average of $11.14.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, research analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current year.
Insider Activity
In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Eric Venker sold 218,041 shares of Roivant Sciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the transaction, the chief operating officer now directly owns 896,869 shares in the company, valued at $9,345,374.98. This trade represents a 19.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,395,541 shares of company stock worth $14,922,538. 7.90% of the stock is currently owned by insiders.
Analysts Set New Price Targets
ROIV has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th.
Check Out Our Latest Analysis on ROIV
Roivant Sciences Company Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
